AZ gets Japanese marketing approval for Zoladex LA
Following a positive report in December from the Pharmaceutical Affairs Council of the Japanese Ministry of Health, Labour and Welfare (MHLW), AstraZeneca has been granted marketing approval in Japan for its prostate cancer treatment Zoladex LA (goselerin acetate 10.8mg). Zoladex LA (Longer Acting) is the first Luteinizing Hormone-Releasing Hormone analogue (LHRHa) available in Japan with an injection that is effective for three months, and adds to the existing widely used 3.6mg monthly depot formulation.
Zoladex is already approved in 78 countries and is a widely prescribed LHRHa therapy administered by subcutaneous depot injection. It works by reducing testosterone production. Benefits of the longer acting formulation include a more convenient therapy and improved patient compliance.